Global Psoriatic Arthritis Therapeutics Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Psoriatic Arthritis Therapeutics Market 2021 (Includes Business Impact of COVID-19)
Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.
Request Covid - 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview


Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.


Global Psoriatic Arthritis Therapeutics Market: Dynamics


Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.


Global Psoriatic Arthritis Therapeutics Market: Segment Analysis


Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.


Global Psoriatic Arthritis Therapeutics Market: Trends


The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.


Global Psoriatic Arthritis Therapeutics Market: Regional Analysis


In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

  
Nonsteroidal anti-inflammatory drug (NSAID)
  
Disease-modifying antirheumatic drug (DMARD)
  
Biologic drug
  
Enzyme inhibitor

Segmentation by diseases type:

  
Asymmetric Psoriatic Arthritis
  
Symmetric Psoriatic Arthritis
  
Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
  
Spondylitis
  
Arthritis Mutilans


Key Market Players included in the report:


  
Abbott Laboratories
  
Amgen Inc.
  
AstraZeneca
  
Biogen Inc.
  
Bristol-Myers Squibb Company
  
Celgene Corporation (Bristol-Myers Squibb)
  
Eisai Inc
  
Eli Lilly and Company
  
Janssen Global Services LLC (Johnson & Johnson)
  
Johnson & Johnson Services Inc.
  
Merck & Co
  
Novartis AG
  
Otsuka Pharmaceutical
  
Pfizer, Inc.
  
Sanofi S.A.
  
Sumitomo Dainippon Pharma Co
  
UCB Biosciences Inc


Below are the key development related to Psoriatic Arthritis Therapeutics Market in 2020 and 2021.


July 2021: Amgen Announces 2021 Third Quarter Dividend. Amgen (NASDAQ: AMGN) announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will be paid on September 8, 2021, to all stockholders of record as of the close of business on August 17, 2021.  Source

July 2021: Amgen To Acquire Privately Held Teneobio For $900 million In Cash With Future Contingent Milestone Payments. Acquisition Complements Amgens Antibody Research Capabilities Across Therapeutic Areas. Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. Amgen (NASDAQ: AMGN) and Teneobio  announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash. The acquisition includes Teneobios proprietary bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules that have the potential to treat a wide range of important diseases across Amgens core therapeutic areas. These platforms complement Amgens existing antibody capabilities with the addition of a heavy-chain only platform that allows a streamlined, sequence-based discovery approach for target binders, as well as Teneobios novel T-cell engager platform, which expands on Amgens existing leadership position in bispecific T-cell engagers by providing a differentiated, but complementary, approach to Amgens current BiTE® platform. Source

May 2021: FDA Accepts Amgens Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis. Potential to Be First and Only Approved Oral Therapy for the Mild-to-Moderate Patient Population. Acceptance Based on Data From Phase 3 ADVANCE Study, Demonstrating Clinically Meaningful Improvements Through Week 32. Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021. "Otezla has been prescribed to hundreds of thousands of patients with moderate-to-severe plaque psoriasis. Based on the positive Phase 3 ADVANCE data, we believe it could play an important role in addressing the unmet need for adults affected by mild-to-moderate plaque psoriasis who have had challenges managing their disease with existing topical therapies alone," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "The FDAs acceptance of this sNDA for Otezla is a significant milestone toward achieving our goal of potentially providing the first and only oral treatment option for the underserved mild-to-moderate patient population. Source

March 2020: Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study. Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial. The overall safety profile of deucravacitinib in this study was consistent with previously reported Phase 2 results. POETYK PSO-1 is the first Phase 3 trial evaluating the efficacy and safety of deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases.

Bristol Myers Squibb (NYSE:BMY) announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-1 evaluated 6 mg of deucravacitinib once daily and met both co-primary endpoints versus placebo, with more patients achieving Psoriasis Area and Severity Index (PASI) 75, defined as at least a 75 percent improvement in PASI, and a static Physician’s Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib. The trial also met multiple key secondary endpoints, including showing deucravacitinib was superior to Otezla® (apremilast) in the proportion of patients reaching a PASI 75 response and sPGA 0/1 at Week 16. The overall safety profile of deucravacitinib in the POETYK PSO-1 trial was consistent with previously reported Phase 2 results. Source